KKL 顾客使用本产品发表的 0 篇科研文献

DSPE-PEG2000-RVG29 is a PEG conjugate composed of DSPE and rabies virus glycoprotein 29 (RVG29). RVG29 specifically binds to nicotinic acetylcholine receptors (nAChR) at the blood-brain barrier (BBB), crosses the BBB, and mediates receptor-dependent transcytosis. DSPE-PEG2000-RVG29 can be used for brain-targeted drug delivery, surface modification of nanocarriers, as well as gene and nucleic acid delivery. DSPE-PEG2000-RVG29 is applicable to research related to hypoxic-ischemic brain injury, Parkinson's disease, and other conditions.

DSPE-PEG2000-RVG29 modified M-R@siC-NPs It has a uniform particle size distribution, near neutral surface charge, efficient siRNA loading capacity, and long-term structural stability in biological media.
DSPE-PEG2000-RVG29-containing  M-R@siC-NPs (20-120 μg/mL; 24 h) exhibits low cytotoxicity in primary astrocytes, with no significant toxicity at concentrations up to 80 μ g/mL, but cell survival rate decreases at higher doses.
DSPE-PEG2000-RVG29-functionalized BAELPP (0.5 μg DNA equivalent per well; High transfection efficiency and low cytotoxicity were achieved in human neuroblastoma SH-SY5Y cells at 24 h/48 h.

M-R@siC-NPs (including DSPE-PEG2000-RVG29) (80 μg/mL; intraperitoneal injection) can effectively inhibit the activation of hippocampal astrocytes in HIBD neonatal mice, alleviate neuroinflammation, and improve their motor coordination and spatial memory.
DSPE-PEG2000-RVG29 (10 mol%; orbital injection) modification can enhance the brain targeting of lipid polymer complexes, thereby achieving upregulation and regional distribution of transgenic expression in the striatum and substantia nigra of mice.

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)